Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Mesothelioma × dostarlimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Endometrial Neoplasms 7 Ovarian Neoplasms 6 Neoplasms 6 Uterine Cervical Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 3 Rectal Neoplasms 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Lung Neoplasms 2 Fallopian Tube Neoplasms 2 Carcinoma, Neuroendocrine 2 Breast Neoplasms 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Clear Cell 1 Sarcoma 1 Recurrence 1 Penile Neoplasms 1 Pathologic Complete Response 1 Neoplasms, Second Primary 1 Multiple Myeloma 1 Mesothelioma, Malignant 1 Mesothelioma 1 Melanoma 1

Interventions

Pemetrexed 10 Gemcitabine 8 Cisplatin 8 Nivolumab 4 Carboplatin 4 niraparib 3 durvalumab 3 Vinorelbine 3 Ipilimumab 3 Bevacizumab 3 tremelimumab 2 pembrolizumab 2 olaparib 2 anetumab ravtansine 2 Radiotherapy, Intensity-Modulated 2 Imatinib Mesylate 2 Fluorodeoxyglucose F18 2 vandetanib 1 tazemetostat 1 sargramostim 1 ribociclib 1 fludarabine phosphate 1 fludarabine 1 dostarlimab 1 defactinib 1 decitabine and cedazuridine drug combination 1 bintrafusp alfa protein, human 1 Zoledronic Acid 1 Vitamin B 12 1 Valproic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04940637 2023-05-12

UNITO-001

University of Turin, Italy

Phase 2 Unknown

Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡